Oncoinvent ASA: Share capital decrease completed

Oslo, Norway, 5 May 2026: Reference is made to the stock exchange announcement made by Oncoinvent ASA (the "Company") on 8 January 2026 regarding the resolution by the extraordinary general meeting to decrease the share capital of the Company by NOK 222,800,997, from NOK 223,920,600 to NOK 1,119,603, through a reduction of the nominal value of the shares by NOK 49.75, from NOK 50 to NOK 0.25.

The resolution was published by the Norwegian Register of Business Enterprises on 22 January 2026 and followed by a six-week creditor notice period, which was completed without creditor objections.

The share capital decrease has today been registered as completed by the Norwegian Register of Business Enterprises. Following the share capital decrease, the share capital of the Company is NOK 1,119,603, divided into 4,478,412 shares, each with a nominal value of NOK 0.25.

For further information, please contact:

Oystein Soug, Chief Executive Officer Email: IR@oncoinvent.com (soug@oncoinvent.com)

This information is subject to the disclosure requirements pursuant to Euronext Oslo Rule Book II for companies listed on Oslo Børs and Section 5-12 of the Norwegian Securities Trading Act.

About Oncoinvent

Oncoinvent is developing Radspherin[®], a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.

This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin[®] stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent's product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.

Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).